Jose Bigles Geigel, MD
Ophthalmology · Covington, GANPI 1821171661
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $56,649 of the $78,077 with a category attached, or 72.6%. 30 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 52.7% of the total. Reporting peaked in 2024 at $33,393 and has fallen 51.7% since, to $16,142 in 2025. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 370 payments — averaging $211.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$41K
- Rxsight Inc$19K
- Carl Zeiss Meditec USA, Inc.$8K
- Glaukos Corporation$3K
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$714
- plus $4K from 24 others
Across 4 payments — averaging $9500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$38K
What the payments were for
- Consulting fees$56,64973%
- Speaking & faculty fees$7101%
- Food & beverage$12,69816%
- Gifts$1350%
- Other$7,88510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 79 | $41,116 |
| Rxsight Inc | 16 | $19,240 |
| Carl Zeiss Meditec USA, Inc. | 2 | $8,014 |
| Glaukos Corporation | 46 | $3,415 |
| AbbVie(2 entities) | 62 | $1,445 |
| Sun Pharmaceutical Industries Inc. | 26 | $714 |
| Alcon | 32 | $684 |
| Bausch & Lomb Americas Inc. | 19 | $464 |
| Notal Vision, Inc. | 2 | $422 |
| Tarsus Pharmaceuticals, Inc. | 7 | $295 |
| Eyepoint US, Inc. | 5 | $290 |
| Biotissue Holdings Inc. | 8 | $286 |
| Dompe US, Inc. | 9 | $256 |
| Sight Sciences, Inc. | 6 | $240 |
| Novartis | 12 | $217 |
| Aerie Pharmaceuticals, Inc. | 4 | $147 |
| Genentech USA, Inc. | 1 | $130 |
| Amgen | 6 | $120 |
| Oyster Point Pharma, Inc. | 6 | $113 |
| Kala Pharmaceuticals, Inc. | 5 | $106 |
| Eyevance Pharmaceuticals LLC | 4 | $75 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $65 |
| Harrow Eye, LLC | 2 | $56 |
| NEW World Medical,inc. | 1 | $55 |
| Staar Surgical Company | 1 | $25 |
| Thea Pharma Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Omeros Corporation | 1 | $16 |
| LKC Technologies, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$38,639
- RXSIGHT CONTACT LENS$18,815
- RXSIGHT INJECTOR CARTRIDGE$18,815
- RXSIGHT INJECTOR HANDPIECE$18,815
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$18,815
- LIGHT ADJUSTABLE LENS (LAL)$18,815
- LUMERA 300$7,885
- Tecnis Simplicity$795
- KXL System$429
- VERITAS Vision System$380
- Photrexa$347
- Photrexa Viscous and Photrexa$330
- CE-marked KXLA system$317
- iDoseTR$265
- DEXYCU$250
- iStent inject W$172
- XDEMVY$159
- Clareon$147
- OMNI(R) SURGICAL SYSTEM (US)$146
- Prokera$144
How this compares
$78,077 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 95 | $132,027 |
| XiidraLifitegrast | 79 | $104,365 |
| LumiganBimatoprost | 112 | $69,826 |
| TyrvayaVarenicline Tartrate | 51 | $42,929 |
| XdemvyLotilaner | 23 | $42,349 |
| CombiganBrimonidine Tartrate/Timolol | 112 | $40,961 |
| Cyclosporine | 43 | $24,204 |
| CequaCyclosporine | 24 | $19,258 |
| Lotemax SmLoteprednol Etabonate | 75 | $19,253 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 96 | $17,968 |
| RocklatanNetarsudil Mesylat/Latanoprost | 39 | $16,783 |
| RhopressaNetarsudil Mesylate | 29 | $15,708 |
| Brimonidine Tartrate | 148 | $13,277 |
| Loteprednol Etabonate | 80 | $11,900 |
| Prednisolone Acetate | 172 | $9,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,445 | $252,249348 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $464 | $112,304101 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $113 | $42,92951 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $295 | $42,34923 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $147 | $32,49168 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $65 | $31,152155 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $714 | $19,25824 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $106 | $6,47513 claims |
| AlconSimbrinza | $684 | $6,45126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Covington
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Jack ChapmanGainesville$244K
- Gregory LeeCumming$214K
- Puneet PandaMarietta$185K
- Jeffrey TranSuwanee$150K
- Evan SchoenbergAtlanta$130K
- Niraj DesaiCumming$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.